• Citer

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.

par Sternberg, C N;Dumez, Herlinde;Van Poppel, H;Skoneczna, I;Sella, A;Daugaard, G;Gil, Thierry ;Graham, J;Carpentier, Paul;Calabro, F;Collette, Laurence;Lacombe, Denis;EORTC Genitourinary Tract Cancer Group,
Référence Annals of oncology, 20, 7, page (1264-1269)
Publication Publié, 2009-07

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.
Auteur:	Sternberg, C N; Dumez, Herlinde; Van Poppel, H; Skoneczna, I; Sella, A; Daugaard, G; Gil, Thierry; Graham, J; Carpentier, Paul; Calabro, F; Collette, Laurence; Lacombe, Denis; EORTC Genitourinary Tract Cancer Group,
Informations sur la publication:	Annals of oncology, 20, 7, page (1264-1269)
Statut de publication:	Publié, 2009-07
Sujet CREF:	Cancérologie
MeSH keywords:	Aged
	Aged, 80 and over
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Castration
	Dose-Response Relationship, Drug
	Drug Administration Schedule
	Humans
	Infusions, Intravenous
	Male
	Middle Aged
	Prostate-Specific Antigen
	Prostatic Neoplasms -- drug therapy -- pathology
	Taxoids -- administration & dosage
	Thionucleotides -- administration & dosage
	Treatment Outcome
Note générale:	Clinical Trial, Phase II
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdn784
	info:pii/mdn784
	info:scp/67650360358
	info:pmid/19297314